For instance, anti‐CD47 associated with Rituximab showed promising activity in heavily pre‐treated NHL (DLBCL and Follicular Lymphoma), obtaining clinical response even in those patients with diseases that were refractory to Rituximab.11 This evidence concerns the gene CD47 and non-Hodgkin lymphoma.